NASDAQ:ARDXArdelyx Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ardelyx Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $6.42 -0.18 (-2.73 %) (As of 07/10/2020 04:00 PM ET) Add Compare Share Today's Range$6.42Now: $6.42▼$6.6850-Day Range$6.22MA: $7.02▼$7.8652-Week Range$2.10Now: $6.42▼$8.81Volume423,100 shsAverage Volume899,200 shsMarket Capitalization$570.93 millionP/E RatioN/ADividend YieldN/ABeta2.02 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingArdelyx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.00, Ardelyx has a potential upside of 86.9% from its current price of $6.42.Amount of Analyst CoverageArdelyx has only been the subject of 1 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesArdelyx has received 476 “outperform” votes. (Add your “outperform” vote.)Underperform VotesArdelyx has received 420 “underperform” votes. (Add your “underperform” vote.)Community SentimentArdelyx has received 53.13% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Ardelyx and other stocks. Vote “Outperform” if you believe ARDX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ARDX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldArdelyx does not currently pay a dividend.Dividend GrowthArdelyx does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ardelyx insiders have sold 166.58% more of their company's stock than they have bought. Specifically, they have bought $521,579.00 in company stock and sold $1,390,420.00 in company stock.Percentage Held by InsidersOnly 15.31% of the stock of Ardelyx is held by insiders.Percentage Held by Institutions86.08% of the stock of Ardelyx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ardelyx are expected to grow in the coming year, from ($1.05) to ($0.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ardelyx is -4.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ardelyx is -4.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArdelyx has a P/B Ratio of 3.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.57 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARDX Previous Symbol CUSIPN/A CIK1437402 Webwww.ardelyx.com Phone510-745-1700Debt Debt-to-Equity Ratio0.26 Current Ratio9.76 Quick Ratio9.76Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$5.28 million Price / Sales108.13 Cash FlowN/A Price / Cash FlowN/A Book Value$2.10 per share Price / Book3.06Profitability EPS (Most Recent Fiscal Year)($1.47) Net Income$-94,940,000.00 Net Margins-1,403.90% Return on Equity-77.23% Return on Assets-48.46%Miscellaneous Employees88 Outstanding Shares88,930,000Market Cap$570.93 million Next Earnings Date8/14/2020 (Estimated) OptionableOptionable NASDAQ:ARDX Rates by TradingView Receive ARDX News and Ratings via Email Sign-up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter. Ardelyx (NASDAQ:ARDX) Frequently Asked Questions How has Ardelyx's stock been impacted by COVID-19 (Coronavirus)? Ardelyx's stock was trading at $5.98 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ARDX stock has increased by 7.4% and is now trading at $6.42. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Ardelyx? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ardelyx. When is Ardelyx's next earnings date? Ardelyx is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Ardelyx. How were Ardelyx's earnings last quarter? Ardelyx Inc (NASDAQ:ARDX) posted its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.25) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.25) by $0.00. The biopharmaceutical company had revenue of $1.21 million for the quarter, compared to analysts' expectations of $0.90 million. Ardelyx had a negative net margin of 1,403.90% and a negative return on equity of 77.23%. View Ardelyx's earnings history. What price target have analysts set for ARDX? 5 brokerages have issued 1 year price objectives for Ardelyx's shares. Their forecasts range from $9.00 to $15.00. On average, they anticipate Ardelyx's stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 86.9% from the stock's current price. View analysts' price targets for Ardelyx. Has Ardelyx been receiving favorable news coverage? Media headlines about ARDX stock have trended very negative on Monday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Ardelyx earned a media sentiment score of -3.2 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about Ardelyx. Who are some of Ardelyx's key competitors? Some companies that are related to Ardelyx include SAGE Therapeutics (SAGE), Turning Point Therapeutics (TPTX), IGM Biosciences (IGMS), Principia Biopharma (PRNB), Uniqure (QURE), Corcept Therapeutics (CORT), Eidos Therapeutics (EIDX), Ligand Pharmaceuticals (LGND), Dicerna Pharmaceuticals (DRNA), Prestige Consumer Healthcare (PBH), Xencor (XNCR), I-Mab (IMAB), Aurinia Pharmaceuticals (AUPH), Intra-Cellular Therapies (ITCI) and Myovant Sciences (MYOV). View all competitors. What other stocks do shareholders of Ardelyx own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ardelyx investors own include Micron Technology (MU), Gilead Sciences (GILD), Catalyst Pharmaceuticals (CPRX), Corbus Pharmaceuticals (CRBP), BioCryst Pharmaceuticals (BCRX), ImmunoGen (IMGN), SCYNEXIS (SCYX), AbbVie (ABBV), NVIDIA (NVDA) and Rigel Pharmaceuticals (RIGL). Who are Ardelyx's key executives? Ardelyx's management team includes the following people: Mr. Michael G. Raab, Pres, CEO & Director (Age 55, Pay $988k)Ms. Elizabeth A. Grammer, Chief Legal & Admin. Officer and Sec. (Age 56, Pay $596k)Mr. David Rosenbaum, Chief Devel. Officer (Age 59, Pay $617.25k)Mr. Keith Santorelli, Acting Principal Financial & Accounting Officer (Age 46)Mr. Jeffrey W. Jacobs, Chief Scientific Officer (Age 57) What is Ardelyx's stock symbol? Ardelyx trades on the NASDAQ under the ticker symbol "ARDX." How do I buy shares of Ardelyx? Shares of ARDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Ardelyx's stock price today? One share of ARDX stock can currently be purchased for approximately $6.42. How big of a company is Ardelyx? Ardelyx has a market capitalization of $570.93 million and generates $5.28 million in revenue each year. The biopharmaceutical company earns $-94,940,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis. Ardelyx employs 88 workers across the globe. What is Ardelyx's official website? The official website for Ardelyx is www.ardelyx.com. How can I contact Ardelyx? Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company can be reached via phone at 510-745-1700 or via email at [email protected] This page was last updated on 7/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
